We are thrilled to announce that ByoRNA has successfully raised $1,500,000 in our latest funding round—a significant milestone that will propel our vision of revolutionizing mRNA production into a new phase of growth and impact. At ByoRNA, we harness the power of eukaryotic cells as natural biofactories, producing high-quality messenger RNA (mRNAs) with unprecedented efficiency. Our cutting-edge bioproduction technology is engineered to mass-produce mRNA and enhance productivity at a mere fraction of the current costs, reshaping the economics of mRNA synthesis and opening up new possibilities for medical treatments and sustainable practices. This injection of capital will enable us not only to scale our operations but also to accelerate research and development initiatives around our innovative, yet often overlooked, method of mRNA production. With this infusion of funds, we are poised to expand our manufacturing capabilities, invest in state-of-the-art equipment, and attract top talent in the biotechnology field to refine and optimize our processes further. The strategic use of these resources will help us better serve critical sectors, from expediting life-saving cancer treatments to contributing to broader solutions for climate resilience. In essence, our mission is a dual one: to build a more sustainable planet and secure a healthier future for generations to come. Together with our investors and dedicated team, we believe that our breakthrough approach to mRNA synthesis will set a new standard in biotechnology and catalyze transformative changes in healthcare and environmental stewardship. This funding round marks the beginning of an exciting chapter, and we invite you to join us on this journey toward a brighter, more sustainable future.

bYoRNA Secures $1.5M Seed Funding to Revolutionize Sustainable mRNA Production
Get the full bYoRNA company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Alitheon
Alitheon provides the last solution you will need for identification, authentication, and traceability of parts and products with our fail-proof, simple-to-use FeaturePrint system. FeaturePrint is an advanced machine-vision technology that provides for items, what fingerprints are for people – a unique and persistent identifier for the one in millions. FeaturePrint serializes items. As such, it enables track & trace, eliminates counterfeits and gray markets, and reduces human error ....all with just a photo using a standard camera. No bar codes, No QR codes, No stickers, No tags, No 'invisible' dust, No markers, No holograms, No special cameras, No special lighting, No Nonsense!
$8.0M Series a
today

The Ryl Company™
The Ryl Company™ is The Modern Tea Company — where nostalgic taste, clean ingredients, and functional benefits come together. Our flagship brand, Ryl Tea, reimagines the classic tea experience with zero sugar, 5 calories or less, nothing artificial, and antioxidant-powered functionality. We believe better-for-you should taste like the flavors you grew up loving. That’s why we exist: to help people Rethink Your Liquids (RYL). Available nationwide.
$20.0M Series c
today

Tavo Biotherapeutics
Tavo Biotherapeutics is developing innovative treatments to address critical unmet needs in ophthalmology. TAV-001 engages two novel targets that represent fundamental mechanisms underlying the pathology of glaucoma-related neurodegeneration. In pre-clinical studies, TAV-001 has shown signals of neuroprotection as well as substantial reduction in intraocular pressure, suggesting that it could represent the first disease-modifying pharmaceutical therapy for these patients. TAV-001 is expected to enter a Phase 1 clinical trial in glaucoma patients in 2025. TAV-002 represents a potential first-in-class treatment for retinal disease, including diabetic retinopathy, diabetic macular edema, and both wet and dry age-related macular degeneration. Tavo has initiated IND-enabling activities for this program.
$17.0M Series a
today

Adaptive Innovations Corp
Adaptive Innovations is an engineering firm and system integrator specializing in the design, fabrication, integration, and installation of custom equipment, automation & robotic solutions, tooling, fixtures, and gages. Comprised of a diverse group of professional engineers with backgrounds in design, controls, manufacturing, and electrical engineering disciplines, our outstanding team can help position your company to compete in today’s global economy. Combining industry best designs with exceptional process knowledge, fed by cross-industry exposure, Adaptive sets itself apart from its competition through every step of a project. We have a history of consistently delivering cost effective solutions, an excellent on-time delivery record, and unparalleled customer service, making Adaptive the engineering partner you can count on. Adaptive is considered the market leader in the design and fabrication of environmental test fixtures for testing such as HALT/HASS, ESS, and ED vibration or combined environments. We have experience with a wide array of automated solutions, including, assembly, pick-n-place, adhesive dispense, soldering, sorting, inspection etc. We're a Fanuc approved integrator, and have also integrated robots from ABB, Epson, Denso, and Adept. Our controls engineers are familiar with Beckhoff, Allen Bradley, Fanuc, Siemens, Mitsubishi, and National Instruments, contrllers and have a wide range of experience with robotic applications.
$50.0M Series a
today

Mia Health
Mia Health provides accurate risk assessments of large groups or populations which is crucial for the efficiency and resource optimization of health systems. With our customizable rapid screening and risk stratification platform you can now scale health systems significantly for more efficient and cost-effective population health management. Mia Health enables anyone to rapidly screen and stratify patient risk profiles using data collected through a smartphone in just 60 seconds. By measuring key vitals and providing critical insights to inform clinical or systemic decision-making, Mia Health simultaneously enables patient recommendations once a clinical decision has been made. Our proprietary cognitive AI encodes the expertise of dozens of world leading physicians making the Mia Health platform the most informed health stratification tool in the world and the only one of its kind. This eagerly anticipated and desperately needed technology is drastically closing the gap on delivering accessible, equitable care to all those who need it regardless of geographic location, economic status, race or gender. Learn More: https://www.miahealth.io
$920.0K Seed
today
Other recent Seed rounds
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Mia Health United States | Seed | $920.0K | today |
| 2 | ![]() Building Better Futures, LLC United States | Seed | $652.8K | today |
| 3 | ![]() ZeroDrift United States | Seed | $10.0M | today |
| 4 | ![]() AstriVax Therapeutics Belgium | Seed | $34.9M | today |
| 5 | ![]() SpeedLabs United States | Seed | $6.5M | today |



